Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBL-001
- Development stage
- Preclinical
- Lead developer
- Sable Therapeutics
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
01
Overview
SBL-001 is a novel polycation nanomedicine being developed by Sable Therapeutics for the treatment of obesity. It is described as uniquely engineered for selective reduction of fat cell volume, representing a new molecular entity in the field of obesity therapies. The precise mechanism of action has not been publicly defined as of the latest available information. The drug originated from research at Columbia University and remains in early-stage development, with no clinical trials or regulatory approvals reported to date[2][3][9].
Beyond the preview
Go deeper on SBL-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBL-001.